BS_PK18H7E7
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 211.07095926412615
- age_years
- 0.671
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.508
- ALLOGRAFT_REJECTION+0.489
- INFLAMMATORY_RESPONSE+0.464
- INTERFERON_ALPHA_RESPONSE+0.464
- INTERFERON_GAMMA_RESPONSE+0.462
- COMPLEMENT+0.400
- KRAS_SIGNALING_UP+0.385
- COAGULATION+0.362
- HEDGEHOG_SIGNALING+0.345
- IL2_STAT5_SIGNALING+0.321
Top 10 suppressed
- E2F_TARGETS-0.501
- MYC_TARGETS_V1-0.457
- G2M_CHECKPOINT-0.450
- MITOTIC_SPINDLE-0.306
- DNA_REPAIR-0.273
- UNFOLDED_PROTEIN_RESPONSE-0.238
- MTORC1_SIGNALING-0.227
- SPERMATOGENESIS-0.195
- PEROXISOME-0.132
- OXIDATIVE_PHOSPHORYLATION-0.129
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_1RXZ3BP7 | low-grade glioma | — | 0.901 |
| 2 | SJBT031351_D1.RNA-Seq | EPN | Supratentorial EPN | 0.891 |
| 3 | TCGA-49-6744-01A-11R-1858-07 | — | cohortA1 | 0.884 |
| 4 | SRR22247245 | — | cohortMD2 | 0.883 |
| 5 | sclc0617_S65.txt | — | cohortMD2 | 0.882 |
| 6 | TCGA-L9-A743-01A-43R-A39D-07 | — | cohortA1 | 0.882 |
| 7 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.877 |
| 8 | TCGA-22-4596-01A-01R-1201-07 | — | cohortA1 | 0.877 |
| 9 | 2833b2f4-e943-4570-96c2-a42c127cd1fa | — | — | 0.874 |
| 10 | BS_4EN8D8Y4 | low-grade glioma | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.508 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.489 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.464 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.464 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.462 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.385 | Inavolisib | — uncovered |
| COAGULATION | 0.362 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.345 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.321 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.299 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.283 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.236 | Inavolisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.174 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.162 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.129 | Cobimetinib | — uncovered |
| HEME_METABOLISM | 0.111 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.093 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.089 | Remibrutinib | — uncovered |